MTIC-d3

• Description :

  MTIC-d3 is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ) . MITC has lower bioavailability in the brain compared with TMZ, because the agent’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane[1].

• UNSPSC :

  12352005

• Target :

  Drug Metabolite; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Metabolic Enzyme/Protease; Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Neurological Disease

• Solubility :

  10 mM in DMSO

• Smiles :

  NC(C1=C(N=CN1)/N=N/NC([2H])([2H])[2H])=O

• Molecular Formula :

  C5H5D3N6O

• Molecular Weight :

  171.18

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1185242-69-6]